CAR-T cells: prospective genetic engineering approach to orchestrate solid tumor in lung cancer

Introduction: Various strategies, starting with surgery, systemic radiation therapy with cytotoxic chemotherapy, and immunotherapy, have been carried out to address mortality from lung cancer. None of these therapies has showed remarkably successful treatments for lung cancer. Developing technology leads to innovation of cancer-targeted therapy as an ideal strategy. Chimeric antigen receptor T cells (CAR-T cells) are one of the novel immunotherapy approaches in genetic engineering. CAR-T therapy has showed promising results as the cancer-targeted therapy. Methods: This review identifies relevant research by the keywords “Lung Cancer”, “CAR-T for Lung Cancer”, “CAR-T for solid tumor”, “CAR-T for SCLC” or “CAR-T for NSCLC”. The articles are extracted from Pubmed, Web of Science, Scopus, Science Direct, and Google Scholar. Data are shown based on discussions of the modification receptor, co-stimulator, and CAR-T cells. Results: CAR-T acts to overcome lung cancer by targeting several receptors, such as mesothelin and c-Met. Several generations have also evolved to more specific and effective therapy. CAR-T modifications like BBIR, SUPRA CAR, and UIR have also been developed to minimize side effects. Conclusion: CAR-T developments are not limited to CAR modification, but include its components and structure.